Drug
Aro Ang 3
Aro Ang 3: highest development phase Phase 2, developed by Arrowhead Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-ANG 3 Injection NCT05217667 | Phase 2 | Homozygous Familial Hypercholesterolemia |
Latest
No recent events.
Follow Aro Ang 3 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.